Dr. Richard Dunne at AIO Discussing Recent Advancements in Colorectal Cancer

Dr. Dunne shared his expertise on, the integration of ctDNA in treatment decisions for colon cancer patients. Then the conversation lead to the significance of next-generation sequencing (NGS) and biomarker testing, followed by insights into the Code Break 301 trial and its potential impact on standard care for chemorefractory colorectal cancer.